Tests a urine test for bladder cancer coming back in people already treated
Studies a urine test to check for return of non-muscle invasive bladder cancer.
Key facts
- Who runs it
- Early is Good Inc.
- Where
- Indianapolis, Little Rock, and St Louis, United StatesSee the 3 sites
- Trial code
- Registry title
- Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 26 Jul 2023
- Planned end
- 31 Aug 2026
- Type of study
- Observational
- Record updated
- 23 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had non-muscle invasive bladder cancer diagnosed in the past 2 years and are having a routine check-up cystoscopy. It tests a urine test (BCDx) to detect cancer coming back.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Non-muscle invasive bladder cancer (NMIBC), newly diagnosed or recurrent, diagnosed within the past 2 years.
- Earlier treatment
- Must be having standard-of-care routine monitoring cystoscopy. No other prior treatment is required.
Main reasons for not taking part
- Planning to have radical cystectomy
- Planning to have chemotherapy-radiation for urothelial cell carcinoma
- Cannot give legally effective informed consent
- Cannot provide at least 30mL of voided urine
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients 18 Years and older
- Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy
- Patients who are able to provide legally effective informed consent
- Patients who are able to provide minimum 30mL of voided urine
Who cannot take part
- Patients planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma
Where in United States
- Indiana University School of MedicineIndianapolis, United StatesContact: Hristos Kaimakliotis, MD (principal investigator)Taking people
- Arkansas Urology Research CenterLittle Rock, United StatesContact: Marotte,Taking people
- Washington UniversitySt Louis, United StatesContact: Eric Kim, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
- Plain-language title
- Tests a urine test for bladder cancer coming back in people already treatedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 April 2026